Towa Pharmaceutical Co Statistics
Towa Pharmaceutical Co (6QC) Stock Statistics & Valuation Metrics
Total Valuation
Towa Pharmaceutical Co has a market cap or net worth of EUR 971.96M. The enterprise value is EUR 375.50B.
- Market Cap
- EUR 971.96M
- Enterprise Value
- EUR 375.50B
Share Statistics
Towa Pharmaceutical Co has 51,516,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 51,516,000
- Owned by Insiders
- ―
- Owned by Institutions
- 9.66%
Financial Efficiency
Towa Pharmaceutical Co’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 2.25%.
- Return on Equity (ROE)
- 0.03
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 2.25%
- Return on Capital Employed (ROCE)
- 0.06
- Revenue Per Employee
- 55.60M
- Profits Per Employee
- 1.07M
- Employee Count
- 4,923
- Asset Turnover
- 0.58
- Inventory Turnover
- 1.41
Valuation Ratios
The current PE Ratio of Towa Pharmaceutical Co is 20.75. Towa Pharmaceutical Co’s PEG ratio is -0.43.
- PE Ratio
- 20.75
- PS Ratio
- 0.61
- PB Ratio
- 0.94
- Price to FCF
- 40.05
- Price to Operating Cash Flow
- 6.79
- PEG Ratio
- -0.43
Income Statement
In the last 12 months, Towa Pharmaceutical Co had revenue of 273.71B and earned 5.25B in profits. Earnings per share was 106.65.
- Revenue
- 273.71B
- Gross Profit
- 99.10B
- Operating Income
- 23.10B
- Pretax Income
- 13.16B
- Net Income
- 5.25B
- EBITDA
- 38.26B
- Earnings Per Share (EPS)
- 106.65
Cash Flow
In the last 12 months, operating cash flow was 25.27B and capital expenditures -20.98B, giving a free cash flow of 4.28B billion.
- Operating Cash Flow
- 25.27B
- Free Cash Flow
- 4.28B
- Free Cash Flow per Share
- 87.02
Dividends & Yields
Towa Pharmaceutical Co pays an annual dividend of ―, resulting in a dividend yield of 2.01%
- Dividend Per Share
- ―
- Dividend Yield
- 2.01%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.48%
- Earnings Yield
- 4.79%
Stock Price Statistics
- Beta
- 0.43
- 52-Week Price Change
- 26.97%
- 50-Day Moving Average
- 19.65
- 200-Day Moving Average
- 20.56
- Relative Strength Index (RSI)
- 47.48
- Average Volume (3m)
- 5
Important Dates
Towa Pharmaceutical Co upcoming earnings date is Feb 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Feb 15, 2027
- Ex-Dividend Date
- ―
Financial Position
Towa Pharmaceutical Co as a current ratio of 2.76, with Debt / Equity ratio of 127.31%
- Current Ratio
- 2.76
- Quick Ratio
- 1.49
- Debt to Market Cap
- 1.08
- Net Debt to EBITDA
- 4.74
- Interest Coverage Ratio
- 10.22
Taxes
In the past 12 months, Towa Pharmaceutical Co has paid 7.91B in taxes.
- Income Tax
- 7.91B
- Effective Tax Rate
- 0.60
Enterprise Valuation
Towa Pharmaceutical Co EV to EBITDA ratio is 8.98, with an EV/FCF ratio of 84.09.
- EV to Sales
- 1.29
- EV to EBITDA
- 8.98
- EV to Free Cash Flow
- 84.09
- EV to Operating Cash Flow
- 14.26
Balance Sheet
Towa Pharmaceutical Co has EUR 42.23B in cash and marketable securities with EUR 229.93B in debt, giving a net cash position of -EUR 187.70B billion.
- Cash & Marketable Securities
- EUR 42.23B
- Total Debt
- EUR 229.93B
- Net Cash
- -EUR 187.70B
- Net Cash Per Share
- -EUR 3,643.49
- Tangible Book Value Per Share
- EUR 3,182.15
Margins
Gross margin is 36.27%, with operating margin of 8.72%, and net profit margin of 2.95%.
- Gross Margin
- 36.27%
- Operating Margin
- 8.72%
- Pretax Margin
- 6.13%
- Net Profit Margin
- 2.95%
- EBITDA Margin
- 14.32%
- EBIT Margin
- 6.23%
Analyst Forecast
The average price target for Towa Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -3.58%
- EPS Growth Forecast
- -51.40%
